Healthcare Policy Experts Urge CMS to Quickly Move on Biogen’s Alzheimer’s Drug
The Food and Drug Administration has approved Biogen’s aducanumab drug for Alzheimer’s disease. Several health policy experts are calling for [...]
Biogen’s Newly Approved Alzheimer’s Drug Features a $56K Price Tag
Biogen’s Aduhelm was recently approved by the Food and Drug Administration for use in Alzheimer’s disease. Its $56,000 yearly price [...]
ICER Considers Payers’ Drug Coverage in Fairness Assessment
The Institute for Clinical and Economic Review (ICER) has decided to expand its role to consider whether a health insurance [...]
Enthusiastic Parents Daunted by $740,000 Epilepsy Drug Price Tag
Parents of children with a rare type of epilepsy were hopeful when they heard about Ravicti, an FDA-approved drug that [...]
PhRMA Sues Federal Government Regarding Medicaid Best Price Ruling
The Pharmaceutical Research and Manufacturers of America (PhRMA) group has sued the Department of Health and Human Services. PhRMA is [...]
CEVR Leaders Discuss Recent Book on Lowering Prescription Drug Costs
An upcoming webinar will feature drug pricing experts and authors of The Right Price: A Value-Based Prescription for Drug Costs. The [...]
Illinois Turns to PBMs to Lower Drug Prices Instead of Centralized Purchasing
Illinois spent around four percent of its $23 billion healthcare budget on drug costs for its Medicaid enrollees. In an [...]
Lupus Foundation Provides Patient Perspective in ICER Drug Assessment
The Institute for Clinical and Economic Review (ICER) reviewed two drugs (voclosporin and belimumab) for use in cases of lupus [...]
Innovent Biologics and Eli Lilly Submit Joint Low-Cost Lung Cancer Drug to FDA
Eli Lilly and Innovent Biologics have partnered to submit an application to the Food and Drug Administration (FDA) for a [...]
Bernstein Analysts Say Value-Based Pricing System Feasible; ICER Assessments Could Lower Pharma Revenue by 15%
One proposed method that could reduce drug prices is the use of a value-based system. A recent report by Bernstein [...]
CEVR Researchers Discuss External Reference Pricing in Reducing Prescription Drug Costs, Note Billions in Potential Savings
Investigators at the Center for the Evaluation and Risk in Health (CEVR) at Tufts Medical Center considered the consequences of external [...]
Prescription Drug Discount Services Not Always Patient-Centered
One of the many ways to purchase prescription drugs is to use a discount program, such as GoodRx or Amazon [...]
Employer Survey Indicates Support for Drug Cost Control Measures
A recent survey indicated that an increasing number of employers support cost-saving measures when it comes to high healthcare costs [...]
Report Details AbbVie’s Substantial Drug Price Increases Amid Profiteering of US Patent System
A recent report details AbbVie’s drug price increases for two leading drugs: Humira and Imbruvica. Humira, used in cases of [...]
CMS Postpones Best Drug Price Requirements Until 2022
A new drug price ruling required a drug’s best listed price to include any discounts. These changes were slated to [...]
Biden’s Pick for CMS Confirmed by Senate, Expected to Push Drug Pricing Legislation
The Biden administration’s pick to lead the Centers for Medicare and Medicaid Services (CMS), Chiquita Brooks-LaSure, has been approved by [...]
Co-Authors Lead Upcoming Webinar on Transitioning to a Value-Based System
Prescription drug prices continue to rise in the United States, leading to an excessive cost burden placed on patients. A [...]
ISPOR Discussion on Value-Based Healthcare
President of Health Platforms at Verily Life Sciences Dr. Vivian Lee shared her thoughts on the shift to value-based healthcare. [...]
Overused Healthcare is Costly and Ineffective
Overdiagnosis and overtreatment in the healthcare field can lead to high patient costs and even cause harm to patients. Unnecessary [...]
Report Suggests Corporate Environmental and Social Goals Should Include ICER Pricing Assessments
Bernstein analysts suggest that companies implementing environment, social, and governance (ESG) actions should consider drug pricing. They might consider incorporating [...]
Senate Finance Committee Member Supports QALYs in Pricing Assessments
Anna Kaltenboeck, a member of the Senate Finance Committee, has publicly expressed her support for quality-adjusted life years (QALYs) as [...]
COVID-19 Pandemic Shines Spotlight on Vaccine Pricing Strategies
As the COVID-19 pandemic continues, conversations regarding vaccine price, access, and healthcare equity are being held around the world. One [...]
PhRMA Overview of Medicare Programs and Coverage
Medicare covers many aspects of medical care. However, it can be confusing to distinguish among Parts A, B, C, and [...]
PhRMA Director Highlights Four Solutions to Lower Healthcare Costs
The COVID-19 pandemic has placed increase strain on the healthcare system. PhRMA Director of Public Affairs Tom Wilbur discusses four [...]
Biosimilar Market to Hit $178 Billion in 2024
In 2006, the European Medicines Agency approved its first biosimilar. Omnitrope was developed in cases of growth hormone deficiency. Now, [...]